KR20170122777A - 트라디피턴트에 의한 치료 방법 - Google Patents

트라디피턴트에 의한 치료 방법 Download PDF

Info

Publication number
KR20170122777A
KR20170122777A KR1020177026588A KR20177026588A KR20170122777A KR 20170122777 A KR20170122777 A KR 20170122777A KR 1020177026588 A KR1020177026588 A KR 1020177026588A KR 20177026588 A KR20177026588 A KR 20177026588A KR 20170122777 A KR20170122777 A KR 20170122777A
Authority
KR
South Korea
Prior art keywords
patient
administering
rti
pruritus
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177026588A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 에이치. 폴리머로폴로스
루이스 윌리엄 리카멜
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020237043041A priority Critical patent/KR102860817B1/ko
Publication of KR20170122777A publication Critical patent/KR20170122777A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Eye Examination Apparatus (AREA)
KR1020177026588A 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법 Ceased KR20170122777A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043041A KR102860817B1 (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043041A Division KR102860817B1 (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Publications (1)

Publication Number Publication Date
KR20170122777A true KR20170122777A (ko) 2017-11-06

Family

ID=55629110

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177026588A Ceased KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020257030197A Pending KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020237043041A Active KR102860817B1 (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257030197A Pending KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020237043041A Active KR102860817B1 (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Country Status (19)

Country Link
US (6) US10463655B2 (https=)
EP (2) EP3730140A1 (https=)
JP (4) JP6891385B2 (https=)
KR (3) KR20170122777A (https=)
CN (2) CN107427502B (https=)
AU (4) AU2016226006B2 (https=)
BR (1) BR112017018620A2 (https=)
CA (2) CA2978736C (https=)
CL (1) CL2017002238A1 (https=)
DK (1) DK3265087T3 (https=)
ES (1) ES2824552T3 (https=)
HR (1) HRP20201627T1 (https=)
HU (1) HUE050944T2 (https=)
IL (1) IL254142B (https=)
MX (2) MX385788B (https=)
PT (1) PT3265087T (https=)
RU (1) RU2770050C2 (https=)
WO (1) WO2016141341A1 (https=)
ZA (1) ZA201706059B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088346A (ko) * 2017-11-17 2020-07-22 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
KR20210067980A (ko) * 2018-09-28 2021-06-08 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978736C (en) * 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
JP2023515167A (ja) * 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (https=) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
EP1394150B1 (en) 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
BR0309486A (pt) 2002-04-26 2005-02-09 Lilly Co Eli Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
NZ580480A (en) * 2003-10-24 2010-02-26 Lilly Co Eli Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
CN101568523A (zh) 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
CN102573475B (zh) 2009-08-14 2016-01-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
PT2722045T (pt) 2009-11-18 2016-10-18 Helsinn Healthcare Sa Composições para o tratamento de náuseas e vómitos mediadas centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2014093907A1 (en) 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112015031724A2 (pt) * 2013-06-24 2017-07-25 Tigercat Pharma Inc uso do antagonista do receptor nk-1 serlopitant em pruridos
CA2978736C (en) * 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
EP3383363B1 (en) 2015-11-30 2021-01-06 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2017112792A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) * 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) * 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088346A (ko) * 2017-11-17 2020-07-22 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
KR20210067980A (ko) * 2018-09-28 2021-06-08 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도

Also Published As

Publication number Publication date
US20190290626A1 (en) 2019-09-26
MX2017011279A (es) 2018-01-25
CN113262221A (zh) 2021-08-17
BR112017018620A2 (pt) 2018-04-17
US10772880B2 (en) 2020-09-15
IL254142B (en) 2022-05-01
AU2016226006A1 (en) 2017-09-21
WO2016141341A1 (en) 2016-09-09
AU2025210905A1 (en) 2025-08-21
US20250205213A1 (en) 2025-06-26
AU2021202956B2 (en) 2023-06-29
JP2024074963A (ja) 2024-05-31
JP2021073258A (ja) 2021-05-13
AU2023233141A1 (en) 2023-10-12
US11324735B2 (en) 2022-05-10
EP3265087B1 (en) 2020-07-22
US12318375B2 (en) 2025-06-03
RU2017134443A3 (https=) 2019-09-05
US20180110761A1 (en) 2018-04-26
JP2023052486A (ja) 2023-04-11
CA2978736C (en) 2023-11-07
US20220226295A1 (en) 2022-07-21
CA2978736A1 (en) 2016-09-09
IL254142A0 (en) 2017-10-31
AU2023233141B2 (en) 2025-05-22
CN107427502A (zh) 2017-12-01
AU2016226006B2 (en) 2021-03-04
CN107427502B (zh) 2021-06-04
KR20230173743A (ko) 2023-12-27
ZA201706059B (en) 2023-08-30
MX385788B (es) 2025-03-18
AU2021202956A1 (en) 2021-06-03
JP6891385B2 (ja) 2021-06-18
MX2021010460A (es) 2021-09-21
RU2017134443A (ru) 2019-04-04
DK3265087T3 (da) 2020-10-19
HUE050944T2 (hu) 2021-01-28
HK1248552A1 (zh) 2018-10-19
HRP20201627T1 (hr) 2021-02-19
ES2824552T3 (es) 2021-05-12
CA3213864C (en) 2026-02-03
NZ735121A (en) 2024-07-26
EP3265087A1 (en) 2018-01-10
KR102860817B1 (ko) 2025-09-16
US10463655B2 (en) 2019-11-05
RU2770050C2 (ru) 2022-04-14
PT3265087T (pt) 2020-10-15
EP3730140A1 (en) 2020-10-28
US20200360358A1 (en) 2020-11-19
CA3213864A1 (en) 2016-09-09
US20190290625A1 (en) 2019-09-26
KR20250136946A (ko) 2025-09-16
JP2018507243A (ja) 2018-03-15
CL2017002238A1 (es) 2018-04-20

Similar Documents

Publication Publication Date Title
US12318375B2 (en) Method of treatment with tradipitant
EP3240538B1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
CN118078835A (zh) 用于夜间尿频的治疗剂
EA038087B1 (ru) Трехкомпонентная фармацевтическая комбинация чистых антагонистов 5-ht6 рецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора, применение указанной комбинации и содержащей ее фармацевтической композиции в лечении когнитивных расстройств и способ такого лечения
WO2010110428A1 (ja) 掻痒の予防及び／または治療剤
TW202327579A (zh) Ｔｅａｄ抑制劑的給藥方案
RU2810253C2 (ru) Способ лечения с применением традипитанта
HK1248552B (en) Method of treatment with tradipitant
CN114761008B (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
CN120302974A (zh) 喹诺林化合物治疗甲状腺癌的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170921

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221017

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230223

Patent event code: PE09021S02D

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20230912

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230223

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20221017

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20230912

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20230522

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20230215